Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
21 December 2021 |
Main ID: |
EUCTR2012-000669-19-IT |
Date of registration:
|
31/08/2012 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE
IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC)
RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN
COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED
PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
(DLBCL).
|
Scientific title:
|
A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE
IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC)
RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN
COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED
PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
(DLBCL). |
Date of first enrolment:
|
11/07/2012 |
Target sample size:
|
600 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000669-19 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Algeria
|
Argentina
|
Belgium
|
Brazil
|
Bulgaria
|
Canada
|
Colombia
|
Finland
|
France
|
Greece
|
India
|
Ireland
|
Israel
|
Italy
|
Netherlands
|
Peru
|
Portugal
|
Russian Federation
|
Saudi Arabia
|
South Africa
|
Spain
|
Thailand
|
Turkey
|
Ukraine
|
United Kingdom
|
Venezuela, Bolivarian Republic of
| | | | | | |
Contacts
|
Name:
|
Head of Clin. Ops Italy
|
Address:
|
V.le G.B. Stucchi 110
20900
Monza (MB)
Italy |
Telephone:
|
+39 039 247 5070 |
Email:
|
ITALY.INFO_CTA@ROCHE.COM |
Affiliation:
|
Roche S.p.A. |
|
Name:
|
Head of Clin. Ops Italy
|
Address:
|
V.le G.B. Stucchi 110
20900
Monza (MB)
Italy |
Telephone:
|
+39 039 247 5070 |
Email:
|
ITALY.INFO_CTA@ROCHE.COM |
Affiliation:
|
Roche S.p.A. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: • Age = 18 and = 80 years at time of study inclusion • Histologically confirmed, previously untreated CD20-positive DLBCL according to the WHO classification system • Patients with an IPI score of 1-5 or IPI score of 0 with bulky disease, defined as one lesion = 7.5 cm • At least one bi-dimensionally measurable lesion defined as = 1.5 cm in its largest dimension on CT scan • Adequate hematologic function • Eastern Cooperative Oncology Group (ECOG) performance status = 2. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 360 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 240
Exclusion criteria: • Histological evidence of transformation of NHL, or types of NHL other than follicular lymphoma • Presence or history of CNS disease • History of malignancy other than follicular NHL which could affect compliance with protocol or interpretation of results • Recent major surgery (within 4 weeks prior to screening, excluding lymph node biopsy).
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Adult patients aged 18-80 years with previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) MedDRA version: 15.1
Level: PT
Classification code 10012818
Term: Diffuse large B-cell lymphoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
|
Intervention(s)
|
Product Name: rituximab/rHuPH20 SC Product Code: RO0452294/F04 Pharmaceutical Form: Solution for injection INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: RO0452294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-
Trade Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: RO0452294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-
|
Primary Outcome(s)
|
Main Objective: To estimate the efficacy in each treatment arm, as measured by complete response (CR) rate 4?8 weeks after the end of treatment.
|
Secondary Objective: • To compare patient satisfaction with rituximab administration (SC versus IV) in patients with DLBCL • To evaluate event-free survival, disease-free survival, progression-free survival and overall survival from randomisation (at least 24 months of follow-up) • To evaluate the safety of rituximab (SC versus IV) in patients with DLBCL
|
Timepoint(s) of evaluation of this end point: The primary analysis of response rate will take place when all patients have completed their induction treatment.
|
Primary end point(s): The primary endpoint of CR/CRu(measured from the day of first rituximab induction dose) will be based on the Investigator's assessment, completed according to the International Working Group response criteria (Cheson et al. 1999) at the end of induction treatment.
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: A preliminary analysis will be performed when all patients have completed their induction treatment. The final analysis of secondary efficacy endpoints (EFS, DFS, PFS and OS) will be provided when the last patient has completed at least 24 months of follow-up after the end of induction treatment, or when one of the following has been documented for all randomized patients: disease recurrence, withdrawal from the study, loss to follow up or death, whichever occurs first.
|
Secondary end point(s): Event-free survival, disease-free survival, progression-free survival and overall survival (EFS, DFS, PFS and OS), patient reported outcomes, administration times and a summary of safety data.
|
Secondary ID(s)
|
2012-000669-19-ES
|
MO28107
|
Source(s) of Monetary Support
|
F. Hoffmann-La Roche Ltd
|
Ethics review
|
Status: Approved
Approval date: 11/07/2012
Contact:
|
|